0001209191-23-016753.txt : 20230307
0001209191-23-016753.hdr.sgml : 20230307
20230307163038
ACCESSION NUMBER: 0001209191-23-016753
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230303
FILED AS OF DATE: 20230307
DATE AS OF CHANGE: 20230307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Taylor Daphne
CENTRAL INDEX KEY: 0001393549
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37746
FILM NUMBER: 23713019
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER NAME:
FORMER CONFORMED NAME: Taylor Daphne L
DATE OF NAME CHANGE: 20070316
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aptevo Therapeutics Inc.
CENTRAL INDEX KEY: 0001671584
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811567056
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2401 4TH AVE.
STREET 2: SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 206-838-0500
MAIL ADDRESS:
STREET 1: 2401 4TH AVE.
STREET 2: SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-03-03
0
0001671584
Aptevo Therapeutics Inc.
APVO
0001393549
Taylor Daphne
C/O APTEVO THERAPEUTICS INC.
2401 4TH AVENUE, SUITE 1050
SEATTLE
WA
98121
0
1
0
0
SVP, CFO
Common Stock
3840
D
Restricted Stock Unit
Common Stock
792
D
Restricted Stock Unit
Common Stock
4750
D
Restricted Stock Unit
Common Stock
13889
D
Stock Option (right to buy)
6.97
2030-02-18
Common Stock
2400
D
Stock Option (right to buy)
8.56
2030-07-27
Common Stock
514
D
Stock Option (right to buy)
8.56
2030-07-27
Common Stock
514
D
Stock Option (right to buy)
8.56
2030-07-27
Common Stock
516
D
Stock Option (right to buy)
8.56
2030-07-27
Common Stock
839
D
Stock Option (right to buy)
33.50
2031-01-29
Common Stock
7125
D
Stock Option (right to buy)
5.30
2032-03-04
Common Stock
4750
D
The Restricted Stock Units ("RSUs") vest in three approximately equal annual installments beginning on January 29, 2022. The RSUs were granted on January 29, 2021. As of the date of this filing, all but 792 shares had vested.
Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
The RSUs vest in three approximately equal annual installments beginning on March 4, 2023. The RSUs were granted on June 7, 2022.
The RSUs vest in two approximately equal annual installments beginning the day immediately prior to the annual anniversary of the grant date. The RSUs were granted on August 9, 2022.
The option vests in three approximately equal annual installments beginning on February 18, 2021. The option was granted on February 18, 2020.
The option vests in three approximately equal annual installments beginning on July 27, 2021. The option was granted on July 27, 2020.
The option vests in three approximately equal annual installments beginning on January 29, 2022. The option was granted on January 29, 2021.
The option vests in three approximately equal annual installments beginning on March 4, 2023. The option was granted on March 4, 2022.
/s/ SoYoung Kwon, Attorney-in-Fact
2023-03-07
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints
SoYoung Kwon as his or her true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer of Aptevo Therapeutics Inc. (the "Company"), Forms 3, 4, and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder, and any other forms or reports the undersigned may be required
to file in connection with the undersigned's ownership, acquisition, or
disposition of securities of the Company;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
or other form or report, and timely file such form or report with the U.S.
Securities and Exchange Commission and any stock exchange or similar authority;
and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in his or
her discretion.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform each and every act and thing whatsoever requisite, necessary,
and proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or his substitute or
substitutes, shall lawfully do or cause to be done by virtue of this Power of
Attorney and the rights and powers herein granted. The undersigned acknowledges
that no such attorney-in-fact, in serving in such capacity at the request of the
undersigned, is hereby assuming any of the undersigned's responsibilities to
comply with Section 13 and Section 16 of the Securities Exchange Act of 1934 and
the rules thereunder, as amended.
This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to the foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 23rd day of January, 2023.
/s/ Daphne Taylor